Related Experiment Videos
[Anti-inflammatory treatment in sepsis]
1Klinik für Anästhesiologie und Intensivtherapie, Klinikum der Friedrich-Schiller-Universität Jena, Germany.
Abstract:
A systemic inflammation with the release of multiple cytokines plays an important role in the pathophysiology of sepsis. During the last years, several anti-inflammatory substances have been investigated with respect to their effects on mortality in patients with sepsis. However, only the antibody fragment of the TNFalpha binding antibody afelimomab and the recombinant human activated protein C (drotrecogin alpha [activated]) were capable of improving the outcome in controlled studies with large sample sizes. The possible administration of these substances should be restricted to patients who meet the inclusion criteria of these studies. In particular, the tight time window, which usually ends 24 h after the onset of sepsis, should be taken into consideration before starting an anti-inflammatory medication. In addition to the anti-inflammatory treatment, the control of the infectious focus and an aggressive hemodynamic stabilization must not be neglected. Ibuprofen, interleukin-1 receptor antagonists and soluble TNFalpha-receptors as well as high dosages of corticosteroids and antithrombin III do not have a place in the anti-inflammatory treatment of sepsis.
Insights
Sepsis treatment involves managing systemic inflammation. Only specific therapies like afelimomab and drotrecogin alpha [activated] show improved outcomes in large studies, requiring strict adherence to criteria.
Area of Science:
- Critical Care Medicine
- Immunology
- Pharmacology
Background:
- Sepsis involves systemic inflammation driven by cytokine release, impacting patient pathophysiology.
- Numerous anti-inflammatory agents have been explored for sepsis, with limited success in improving mortality.
Purpose of the Study:
- To review the efficacy of anti-inflammatory treatments in sepsis.
- To identify therapies that demonstrably improve patient outcomes in large-scale studies.
Main Methods:
- Review of controlled studies investigating anti-inflammatory substances in sepsis patients.
- Analysis of therapies demonstrating significant improvements in mortality or patient outcomes.
Main Results:
- Only afelimomab (TNFalpha binding antibody fragment) and drotrecogin alpha [activated] (recombinant human activated protein C) improved outcomes in large, controlled sepsis studies.
- Effective anti-inflammatory treatment requires strict adherence to patient inclusion criteria and a narrow time window (typically within 24 hours of sepsis onset).
- Certain agents like ibuprofen, IL-1 receptor antagonists, soluble TNFalpha-receptors, high-dose corticosteroids, and antithrombin III are not recommended for anti-inflammatory sepsis treatment.
Conclusions:
- Anti-inflammatory therapy for sepsis is limited to specific agents with proven efficacy in rigorous trials.
- Patient selection and timing are critical for the successful administration of these targeted sepsis treatments.
- Concurrent management of infectious foci and hemodynamic stabilization remains paramount in sepsis care.